

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

SCHEDULES

SCHEDULE 2 U.K.

Section 2.

CONTROLLED DRUGS

PART I U.K.

CLASS A DRUGS

1 The following substances and products, namely:—

- [^{F1}(a)] Acetorphine.
[^{F2}Alfentanil.]
Allylprodine.
Alphacetylmethadol.
Alphameprodine.
Alphamethadol.
Alphaprodine.
Anileridine.
Benzethidine.
Benzylmorphine (3-benzylmorphine).
Betacetylmethadol.
Betameprodine.
Betamethadol.
Betaprodine.
Bezitramide.
Bufotenine.
^{F3} ...
^{F4} ...
[^{F5}Carfentanil.]
Clonitazene.
Coca leaf.
Cocaine.
Desomorphine.
Dextromoramide.
Diamorphine.
Diampromide.
Diethylthiambutene.
[^{F6}Difenoxin (1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid).]
Dihydrocodeinone *O*-carboxymethyloxime.

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

[^{F7}Dihydroetorphine]

Dimenoxadole.

Dimepheptanol.

Dimethylthiambutene.

Dioxaphetyl butyrate.

Diphenoxylate.

Dipipanone.

[^{F8}Drotebanol (3,4-dimethoxy-17-methylmorphinan-6b, 14-diol).]

Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine.

Ethylmethylthiambutene.

[^{F2}Eticyclidine.]

Etonitazene.

Etorphine.

Etoxeridine.

[^{F9}Etryptamine]

Fentanyl.

[^{F10}Fungus (of any kind) which contains psilocin or an ester of psilocin.]

Furethidine.

Hydrocodone.

Hydromorphinol.

Hydromorphone.

Hydroxypethidine.

Isomethadone.

Ketobemidone.

Levomethorphan.

Levomoramide.

Levophenacylmorphan.

Levorphanol.

[^{F5}Lofentanil]

Lysergamide.

Lysergide and other *N*-alkyl derivatives of lysergamide.

Mescaline.

Metazocine.

Methadone.

Methadyl acetate.

[^{F11}Methylamphetamine]

Methyldesorphine.

Methyldihydromorphone (6-methyldihydromorphone).

Metopon.

Morpheridine.

Morphine.

Morphine methobromide, morphine *N*-oxide and other pentavalent nitrogen morphine derivatives.

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

Myrophine.
F12
. . .
Nicomorphine (3,6-dinicotinoylmorphine).
Noracymethadol.
Norlevorphanol.
Normethadone.
Normorphine.
Norpipanone.
Opium, whether raw, prepared or medicinal.
Oxycodone.
Oxymorphone.
Pethidine.
Phenadoxone.
Phenampromide.
Phenazocine.
[F13Phencyclidine.]
Phenomorphane.
Phenoperidine.
Piminodine.
Piritramide.
Poppy-straw and concentrate of poppy-straw.
Proheptazine.
Properidine (1-methyl-4-phenyl-piperidine-4-carboxylic acid isopropyl ester).
Psilocin.
Racemethorphan.
Racemoramide.
Racemorphan.
[F14Remifentanyl]
[F2Rolicyclidine.]
[F15Sufentanyl.]
[F16Tapentadol.]
[F2Tenocyclidine.]
Thebacon.
Thebaine.
[F15Tilidate.]
Trimeperidine.
[F174-Bromo-2,5-dimethoxy- α -methylphenethylamine].
4-Cyano-2-dimethylamino-4,4-diphenylbutane.
4-Cyano-1-methyl-4-phenyl-piperidine.
N,N-Diethyltryptamine.
N,N-Dimethyltryptamine.
2,5-Dimethoxy- α ,4-dimethylphenethylamine.
[F18N-Hydroxy-tenamphetamine.]

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

- 1-Methyl-4-phenylpiperidine-4-carboxylic acid.
2-Methyl-3-morpholino-1, 1-diphenylpropanecarboxylic acid.
[^{F19}4-Methyl-aminorex]
4-Phenylpiperidine-4-carboxylic acid ethyl ester.
- [^{F20}(b) any compound (not being a compound for the time being specified in subparagraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
- [the following phenethylamine derivatives, namely:—
- [^{F21}(ba) Allyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine
2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol
2-Amino-1-(3,4-dimethoxyphenyl)ethanol
Benzyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine
4-Bromo- *b* ,2,5-trimethoxyphenethylamine
N -(4- *sec* -Butylthio-2,5-dimethoxyphenethyl)hydroxylamine
Cyclopropylmethyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine
2-(4,7-Dimethoxy-2,3-dihydro-1 *H* -indan-5-yl)ethylamine
2-(4,7-Dimethoxy-2,3-dihydro-1 *H* -indan-5-yl)-1-methylethylamine
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine
2-(1,4-Dimethoxy-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
N -(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
a , *a* -Dimethyl-3,4-methylenedioxyphenethylamine
a , *a* -Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
Dimethyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine
N -(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
4-Iodo-2,5-dimethoxy- *a* -methylphenethyl(dimethyl)amine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine
2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine
2-Methoxyethyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine
2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine
b -Methoxy-3,4-methylenedioxyphenethylamine
1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
2-(*a* -Methyl-3,4-methylenedioxyphenethylamino)ethanol
a -Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

- N* -Methyl- *N* -(*a* -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
O -Methyl- *N* -(*a* -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
a -Methyl-4-(methylthio)phenethylamine
b ,3,4,5-Tetramethoxyphenethylamine
b ,2,5-Trimethoxy-4-methylphenethylamine;]
- (c) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine an *N* -alkylphenethylamine, *a*-methylphenethylamine, an *N* -alkyl-*a*-methylphenethylamine, *a*-ethylphenethylamine, or an *N* -alkyl-*a*-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylendioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents.]
- [^{F22}(d) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from fentanyl by modification in any of the following ways, that is to say,
- (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
 - (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
 - (iii) by substitution in the piperidine ring with alkyl or alkenyl groups;
 - (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylendioxy, halogeno or haloalkyl groups;
 - (v) by substitution at the 4-position of the piperidine ring with any alkoxy-carbonyl or alkoxyalkyl or acyloxy group;
 - (vi) by replacement of the *N*-propionyl group by another acyl group;
- (e) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from pethidine by modification in any of the following ways, that is to say,
- (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
 - (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
 - (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
 - (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxy-carbonyl or any alkoxyalkyl or acyloxy group;
 - (v) by formation of an *N*-oxide or of a quaternary base.]

[^{F23}(f) any compound (not being benzyl(*a*-methyl-3,4-methylenedioxyphenethyl)amine) structurally derived from mescaline, 4-bromo-2,5-dimethoxy-*a*-methylphenethylamine, 2,5-dimethoxy-*a*,4-dimethylphenethylamine, *N*-hydroxytenamphetamine, or a compound specified in sub-paragraph (ba) or (c) above, by substitution at the nitrogen atom of the amino group with a benzyl substituent, whether or not substituted in the phenyl ring of the benzyl group to any extent.]

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

Textual Amendments

- F1** "(a)" inserted by [S.I. 1977/1243, art. 3\(a\)](#)
- F2** Word inserted by [S.I. 1984/859, art. 2\(2\)](#)
- F3** Words in Sch. 2 Pt. 1 para. 1(a) deleted (29.1.2004) by [The Misuse of Drugs Act 1971 \(Modification\) \(No. 2\) Order 2003 \(S.I. 2003/3201\), art. 2\(2\)](#)
- F4** Words in Sch. 2 Pt. 1 para. 1(a) deleted (29.1.2004) by [The Misuse of Drugs Act 1971 \(Modification\) \(No. 2\) Order 2003 \(S.I. 2003/3201\), art. 2\(2\)](#)
- F5** Word inserted by [S.I. 1986/2230, art. 2\(2\)\(a\)](#)
- F6** Word inserted by [S.I. 1975/421, art. 3](#)
- F7** Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.7.2003) by [The Misuse of Drugs Act 1971 \(Modification\) Order 2003 \(S.I. 2003/1243\), art. 2\(2\)\(a\)](#)
- F8** Word inserted by [S.I. 1973/771, art. 2](#)
- F9** Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.5.1998) by [S.I. 1998/750, art. 2\(2\)](#)
- F10** Words in Sch. 2 Pt. 1 para. 1 inserted (18.7.2005) by [Drugs Act 2005 \(c. 17\), s. 21](#)
- F11** Word in Sch. 2 Pt. 1 para. 1(a) inserted (18.1.2007) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2006 \(S.I. 2006/3331\), art. 2\(1\)](#)
- F12** Words repealed by [S.I. 1973/771, art. 2](#)
- F13** Word inserted by [S.I. 1979/299, art. 2](#)
- F14** Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.7.2003) by [The Misuse of Drugs Act 1971 \(Modification\) Order 2003 \(S.I. 2003/1243\), art. 2\(2\)\(b\)](#)
- F15** Word inserted by [S.I. 1983/765, art. 2\(a\)](#)
- F16** Word in Sch. 2 Pt. 1 para. 1(a) inserted (28.3.2011) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2011 \(S.I. 2011/744\), arts. 1\(1\), 2](#)
- F17** Words inserted by [S.I. 1975/421, art. 3](#)
- F18** Word inserted by [S.I. 1990/2589, art. 2\(a\)\(i\)](#)
- F19** Word inserted by [S.I. 1990/2589, art. 2\(a\)\(ii\)](#)
- F20** Sch. 2 Pt. 1 para. 1(b)(c) added by [S.I. 1977/1243, art. 3\(b\)](#)
- F21** Sch. 2 Pt. 1 para. 1(ba) inserted (1.2.2002) by [The Misuse of Drugs Act 1971 \(Modification\) Order 2001 \(S.I. 2001/3932\), art. 2\(2\)](#)
- F22** Sch. 2 Pt. 1 para. 1(d)(e) added by [S.I. 1986/2230, art. 2\(2\)\(b\)](#)
- F23** Sch. 2 Pt. 1 para. 1(f) inserted (10.6.2014) by [The Misuse of Drugs Act 1971 \(Ketamine etc.\) \(Amendment\) Order 2014 \(S.I. 2014/1106\), art. 3](#)

- 2 Any stereoisomeric form of a substance for the time being specified in paragraph 1 above not being dextromethorphan or dextrorphan.
- 3 Any ester or ether of a substance for the time being specified in paragraph 1 or 2 above [^{F24}not being a substance for the time being specified in Part II of this Schedule].

Textual Amendments

- F24** Words inserted by [S.I. 1973/771, art. 2](#)

- 4 Any salt of a substance for the time being specified in any of paragraphs 1 to 3 above.
- 5 Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 4 above.

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

- 6 Any preparation designed for administration by injection which includes a substance or product for the time being specified in any of paragraphs 1 to 3 of Part II of this Schedule.

PART II **U.K.**

CLASS B DRUGS

- 1 The following substances and products, namely:—
- [^{F25}(a)] Acetyldihydrocodeine.
Amphetamine.
[^{F26}Cannabinol]
[^{F26}Cannabinol derivatives]
[^{F26}Cannabis and cannabis resin]
^{F27}
...
Codeine.
^{F28}
...
Dihydrocodeine.
Ethylmorphine (3-ethylmorphine).
[^{F29}Glutethimide.]
[^{F30}Ketamine.]
[^{F29}Lefetamine.]
[^{F31}Lisdexamphetamine.]
[^{F32}Mecloqualone.]
[^{F32}Methaqualone.]
[^{F33}Methcathinone]
^{F34}
...
^{F35}
...
[^{F36}*α*-Methylphenethylhydroxylamine]
Methylphenidate.
[^{F32}Methylphenobarbitone.]
Nicocodine.
[^{F37}Nicodicodine (6-nicotinoyldihydrocodeine).]
Norcodeine.
[^{F38}Pentazocine.]
Phenmetrazine.
Pholcodine.
[^{F39}Propiram.]
[^{F33}Zipeprol]
[^{F40}2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol.]
- [^{F41}(aa)] Any compound (not being bupropion, cathinone, diethylpropion, pyrovalerone or a compound for the time being specified in subparagraph (a) above) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways, that is to say,

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

- (i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
 - (ii) by substitution at the 3–position with an alkyl substituent;
 - (iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.]
- [^{F42}(ab) Any compound structurally derived from 2–aminopropan–1–one by substitution at the 1–position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylendioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say,
- (i) by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
 - (ii) by substitution at the 3–position with an alkyl substituent;
 - (iii) by substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.]
- [^{F43}(ac) Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say,
- (i) by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups;
 - (ii) by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group;
 - (iii) by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group.]
- [^{F25}(b) any 5,5 disubstituted barbituric acid.]
- [^{F44}(c) [2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–*de*]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone.
[9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate.
[9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate.
9–(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[*c*]chromen–1–ol.
Any compound structurally derived from 3–(1–naphthoyl)indole, 3–(2–naphthoyl) indole, 1*H*–indol–3–yl–(1–naphthyl)methane or 1*H*–indol–3–yl–(2–naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin–2–yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
Any compound structurally derived from 3–(1–naphthoyl)pyrrole or 3–(2–naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin–2–yl)methyl

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

Any compound structurally derived from 1-(1-naphthylmethylene)indene or 1-(2-naphthylmethylene)indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.

Nabilone.

Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.

Any compound structurally derived from 3-benzoylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

Any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent.

Any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent.

- (d) 1-Phenylcyclohexylamine or any compound (not being ketamine, tiletamine or a compound for the time being specified in paragraph 1(a) of Part 1 of this Schedule) structurally derived from 1-phenylcyclohexylamine or 2-amino-2-phenylcyclohexanone by modification in any of the following ways, that is to say,
- (i) by substitution at the nitrogen atom to any extent by alkyl, alkenyl or hydroxyalkyl groups, or replacement of the amino group with

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

- a 1-piperidyl, 1-pyrrolidyl or 1-azepyl group, whether or not the nitrogen containing ring is further substituted by one or more alkyl groups;
- (ii) by substitution in the phenyl ring to any extent by amino, alkyl, hydroxy, alkoxy or halide substituents, whether or not further substituted in the phenyl ring to any extent;
- (iii) by substitution in the cyclohexyl or cyclohexanone ring by one or more alkyl substituents;
- (iv) by replacement of the phenyl ring with a thienyl ring.]
- [^{F45}(e) Any compound (not being a compound for the time being specified in paragraph 1(ba) of Part 1 of this Schedule) structurally derived from 1-benzofuran, 2,3-dihydro-1-benzofuran, 1H-indole, indoline, 1H-indene, or indane by substitution in the 6-membered ring with a 2-ethylamino substituent whether or not further substituted in the ring system to any extent with alkyl, alkoxy, halide or haloalkyl substituents and whether or not substituted in the ethylamino side-chain with one or more alkyl substituents.]

Textual Amendments

- F25** Sch. 2 Pt. 2 para. 1(b) added by [S.I. 1984/859, art. 2\(3\)](#)
- F26** Words in Sch. 2 Pt. 2 para. 1(a) inserted (26.1.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2008 \(S.I. 2008/3130\), art. 2\(2\)\(a\)](#)
- F27** Words in Sch. 2 Pt. 2 para. 1(a) deleted (29.1.2004) by [The Misuse of Drugs Act 1971 \(Modification\) \(No. 2\) Order 2003 \(S.I. 2003/3201\), art. 2\(3\)](#)
- F28** Word repealed by [S.I. 1985/1995, art. 2\(2\)\(a\)](#)
- F29** Word inserted by [S.I. 1985/1995, art. 2\(2\)\(b\)](#)
- F30** Word in Sch. 2 Pt. 2 para. 1(a) inserted (10.6.2014) by [The Misuse of Drugs Act 1971 \(Ketamine etc.\) \(Amendment\) Order 2014 \(S.I. 2014/1106\), art. 4\(a\)\(i\)](#)
- F31** Word in Sch. 2 Pt. 2 para. 1(a) inserted (10.6.2014) by [The Misuse of Drugs Act 1971 \(Ketamine etc.\) \(Amendment\) Order 2014 \(S.I. 2014/1106\), art. 4\(a\)\(ii\)](#)
- F32** Word inserted by [S.I. 1984/859, art. 2\(3\)](#)
- F33** Words in Sch. 2 Pt. 2 para. 1(a) inserted (1.5.1998) by [S.I. 1998/750, art. 2\(3\)](#)
- F34** Word in Sch. 2 Pt. 2 para. 1(a) omitted (28.3.2011) by virtue of [The Misuse of Drugs Act 1971 \(Amendment\) Order 2011 \(S.I. 2011/744\), arts. 1\(1\), 3](#)
- F35** Word in Sch. 2 Pt. 2 para. 1(a) repealed (18.1.2007) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2006 \(S.I.2006/3331\), art. 2\(2\)](#)
- F36** Word in Sch. 2 Pt. 2 para. 1(a) inserted (1.2.2002) by [S.I. 2001/3932, art. 2\(3\)](#)
- F37** Words inserted by [S.I. 1973/771, art. 2](#)
- F38** Word inserted by [S.I. 1985/1995, art. 2\(2\)\(c\)](#)
- F39** Word inserted by [S.I. 1973/771, art. 2](#)
- F40** Words in Sch. 2 Pt. 2 para. 1(a) inserted (26.2.2013) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2013 \(S.I. 2013/239\), art. 3](#)
- F41** Sch. 2 Pt. 2 para. 1(aa) inserted (16.4.2010) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2010 \(S.I. 2010/1207\), art. 2\(b\)](#)
- F42** Sch. 2 Pt. 2 para. 1(ab) inserted (23.7.2010) by [The Misuse of Drugs Act 1971 \(Amendment No. 2\) Order 2010 \(S.I. 2010/1833\), art. 2](#)
- F43** Sch. 2 Pt. 2 para. 1(ac) inserted (13.6.2012) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2012 \(S.I. 2012/1390\), art. 2\(a\)](#)
- F44** Sch. 2 Pt. 2 para. 1(c)(d) substituted (26.2.2013) for Sch. 2 Pt. 2 para. 1(c) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2013 \(S.I. 2013/239\), art. 4](#)

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

F45 Sch. 2 Pt. 2 para. 1(e) inserted (10.6.2014) by [The Misuse of Drugs Act 1971 \(Ketamine etc.\) \(Amendment\) Order 2014 \(S.I. 2014/1106\)](#), art. 4(b)

2 Any stereoisomeric form of a substance for the time being specified in paragraph 1 of this Part of this Schedule.

[^{F46}2A. Any ester or ether of cannabinal or of a cannabinal derivative [^{F47}or of a substance for the time being specified in [^{F48}paragraph 1(ac), (c) or (d)] of this Part of this Schedule.] .]

Textual Amendments

F46 Sch. 2 Pt. 2 para. 2A inserted (26.1.2009) by [Misuse of Drugs Act 1971 \(Amendment\) Order 2008 \(S.I. 2008/3130\)](#), arts. 1(1), **2(2)(b)**

F47 Words in Sch. 2 Pt. 2 para. 2A inserted (23.12.2009) by [Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), arts. 1, **2(2)(b)**

F48 Words in Sch. 2 Pt. 2 para. 2A substituted (26.2.2013) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2013 \(S.I. 2013/239\)](#), art. 5

3 Any salt of a substance for the time being specified in paragraph 1 [^{F49}, 2 or 2A] of this Part of this Schedule.

Textual Amendments

F49 Words in Sch. 2 Pt. 2 para. 3 substituted (26.1.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2008 \(S.I. 2008/3130\)](#), art. **2(2)(c)**

4 Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 3 of this Part of this Schedule, not being a preparation falling within paragraph 6 of Part I of this Schedule.

PART III U.K.

CLASS C DRUGS

1 The following substances, namely:—

- [^{F50}(a)] [^{F51}Alprazolam.]
- [^{F52}Amineptine]
- [^{F53}Aminorex]
- [^{F51}Bromazepam.]
- [^{F54}7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one.]
- Benzphetamine.
- [^{F53}Brotizolam]
- [^{F55}Buprenorphine]
- [^{F51}Camazepam.]
- ^{F56}
...
- ^{F57}
...

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

F58
...
[F59Cathine.]
[F59Cathinone.]
[F51Chlordiazepoxide.]
Chlorphentermine.
[F51Clobazam.]
[F51Clorazepic acid.]
[F51Clonazepam.]
[F51Clotiazepam.]
[F51Cloxazolam.]
[F51Delorazepam.]
[F60Dextropropoxyphene.]
[F51Diazepam.]
[F61Diethylpropion.]
[F51Estazolam.]
[F51Ethchlorvynol.]
[F51Ethinamate.]
[F51Ethyl loflazepate.]
[F59Fencamfamin.]
[F59Fenethylamine.]
[F59Fenproporex.]
[F51Fludiazepam.]
[F51Flunitrazepam.]
[F51Flurazepam.]
[F62Gamma–butyrolactone]
[F51Halazepam.]
[F51Haloxazolam.]
[F634-Hydroxy-n-butyric acid]
F64
...
[F51Ketazolam.]
[F65Khat.]
[F51Loprazolam.]
[F51Lorazepam.]
[F51Lormetazepam.]
[F51Mazindol.]
[F51Medazepam.]
[F59Mefenorex.]
F66
...
Mephentermine.
[F51Meproamate.]

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

[^{F53}Mesocarb]
F67
...
[^{F51}Methyprylone.]
[^{F68}Midazolam.]
[^{F51}Nimetazepam.]
[^{F51}Nitrazepam.]
[^{F51}Nordazepam.]
[^{F51}Oxazepam.]
[^{F51}Oxazolam.]
[^{F69}Pemoline.]
F66
...
Phendimetrazine.
[^{F51}Phentermine.]
[^{F51}Pinazepam.]
F66
...
F70
...
[^{F51}Prazepam.]
F66
...
F71
...
[^{F59}Pyrovalerone.]
[^{F51}Temazepam.]
[^{F51}Tetrazepam.]
[^{F72}Tramadol.]
[^{F51}Triazolam.]
[^{F59}N-Ethylamphetamine.]
[^{F73}Zaleplon.]
[^{F74}Zolpidem]
[^{F75}Zopiclone.]
[^{F76}(b) [^{F77}5 α -Androstane-3,17-diol.]
[^{F78}Androst-4-ene-3,17-diol.]
[^{F79}1-Androstenediol.]
[^{F80}1-Androstenedione]
[^{F81}4-Androstene-3, 17-dione]
[^{F82}5-Androstenedione.]
[^{F81}5-Androstene-3, 17-diol]
Atamestane.
Bolandiol.
Bolasterone.
Bolazine.
Boldenone.
[^{F83}Boldione.]

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

Bolenol.
Bolmantalate.
[^{F84}1,4-Butanediol.]
Calusterone.
4-Chloromethandienone.
Clostebol.
[^{F85}Danazol.]
[^{F86}Desoxymethyltestosterone]
Drostanolone.
Enestebol.
Epitiostanol.
Ethyloestrenol.
Fluoxymesterone.
Formebolone.
Furazabol.
[^{F87}Gestrinone.]
[^{F88}3-Hydroxy-5 α -androstan-17-one.]
Mebolazine.
Mepitiostane.
Mesabolone.
Mestanolone.
Mesterolone.
Methandienone.
Methandriol.
Methenolone.
Methyltestosterone.
Metribolone.
Mibolerone.
Nandrolone.
[^{F89}19-Norandrostenedione.]
[^{F90}19-Nor-4-Androstene-3, 17-dione]
[^{F91}19-Norandrosterone.]
[^{F90}19-Nor-5-Androstene-3, 17-diol]
Norboletone.
Norclostebol.
Norethandrolone.
[^{F92}19-Noretiocholanolone.]
[^{F93}Oripavine.]
Ovandroton.
Oxabolone.
Oxandrolone.
Oxymesterone.
Oxymetholone.
[^{F94}Pipradrol.]

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

- Prasterone.
Propetandrol.
[^{F95}Prostanozolol]
Quinbolone.
Roxibolone.
Silandrone.
Stanolone.
Stanozolol.
Stenbolone.
Testosterone.
[^{F96}Tetrahydrogestrinone.]
Thiomesterone.
Trenbolone.
- (c) any compound (not being Trilostane or a compound for the time being specified in sub-paragraph (b) above) structurally derived from 17-hydroxyandrostane-3-one or from 17-hydroxyestrane-3-one by modification in any of the following ways, that is to say,
- (i) by further substitution at position 17 by a methyl or ethyl group;
 - (ii) by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;
 - (iii) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;
 - (iv) by fusion of ring A with a heterocyclic system;
- [^{F97}(ca) 1-benzylpiperazine or any compound structurally derived from 1-benzylpiperazine or 1-phenylpiperazine by modification in any of the following ways—
- (i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;
 - (ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups.]
- (d) any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in sub-paragraph (b) or described in sub-paragraph (c) above ^{F98}...;
- (e) Chorionic Gonadotrophin (HCG).
Clenbuterol.
Non-human chorionic gonadotrophin.
Somatotropin.
Somatrem.
Somatropin.]
[^{F99}Zeranol.]
[^{F100}Zilpaterol.]

Textual Amendments

F50 "(a)" inserted (1.9.1996) by [S.I. 1996/1300](#), [art. 2\(2\)\(a\)](#)

F51 Word inserted by [S.I. 1985/1995](#), [art. 2\(3\)](#)

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

- F52** Word in Sch. 2 Pt. 3 para. 1(a) inserted (28.3.2011) by The Misuse of Drugs Act 1971 (Amendment) Order 2011 (S.I. 2011/744), **arts. 1(1), 4**
- F53** Words in Sch. 2 Pt. 3 para. 1(a) inserted (1.5.1998) by S.I. 1998/750, **art. 2(4)**
- F54** Words in Sch. 2 Pt. 3 para. 1(a) inserted (13.6.2012) by The Misuse of Drugs Act 1971 (Amendment) Order) 2012 (S.I. 2012/1390), **art. 3(a)(ii)**
- F55** Word inserted by S.I. 1989/1340, **art. 2(a)**
- F56** Word in Sch. 2 Pt. 3 para. 1(a) repealed (26.1.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), **art. 2(3)(a)**
- F57** Words in Sch. 2 Pt. 3 para. 1(a) repealed (26.1.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), **art. 2(3)(a)**
- F58** Words in Sch. 2 Pt. 3 para. 1(a) repealed (26.1.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), **art. 2(3)(a)**
- F59** Word inserted by S.I. 1986/2230, **art. 2(3)**
- F60** Word inserted by S.I. 1983/765, **art. 2(a)**
- F61** Word inserted by S.I. 1984/859, **art. 2(4)(a)**
- F62** Word in Sch. 2 Pt. 3 para. 1(a) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), **art. 2(3)(a)**
- F63** Word in Sch. 2 Pt. 3 para. 1(a) inserted (1.7.2003) by The Misuse of Drugs Act 1971 (Modification) Order 2003 (S.I. 2003/1243), **arts. 1, 2(3)(a)**
- F64** Word in Sch. 2 Pt. 3 para. 1(a) omitted (10.6.2014) by virtue of The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014 (S.I. 2014/1106), **art. 5(a)**
- F65** Word in Sch. 2 Pt. 3 para. 1(a) inserted (24.6.2014) by The Misuse of Drugs Act 1971 (Amendment) Order 2014 (S.I. 2014/1352), **art. 3**
- F66** Words repealed by S.I. 1973/771, **art. 2**
- F67** Word repealed by S.I. 1984/859, **art. 2(4)(a)**
- F68** Word inserted by S.I. 1990/2589, **art. 2(b)**
- F69** Word inserted by S.I. 1989/1340, **art. 2(b)**
- F70** Word in Sch. 2 Pt. 3 para. 1(a) omitted (13.6.2012) by virtue of The Misuse of Drugs Act 1971 (Amendment) Order 2012 (S.I. 2012/1390), **art. 3(a)(i)**
- F71** Word in Sch. 2 Pt. 3 para.1 omitted (1.9.1995) by virtue of S.I. 1995/1966, **art. 2**
- F72** Word in Sch. 2 Pt. 3 para. 1(a) inserted (10.6.2014) by The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014 (S.I. 2014/1106), **art. 5(b)**
- F73** Word in Sch. 2 Pt. 3 para. 1(a) inserted (10.6.2014) by The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014 (S.I. 2014/1106), **art. 5(c)**
- F74** Word in Sch. 2 Pt. 3 para. 1(a) inserted (1.7.2003) by The Misuse of Drugs Act 1971 (Modification) Order 2003 (S.I. 2003/1243), **arts. 1, 2(3)(b)**
- F75** Word in Sch. 2 Pt. 3 para. 1(a) inserted (10.6.2014) by The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014 (S.I. 2011/1106), **art. 5(d)**
- F76** Sch. 2 Pt. 3 para. 1(b)-(e) added (1.9.1996) by S.I. 1996/1300, **art. 2(2)(b)**
- F77** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), **art. 2(3)(b)(i)**
- F78** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), **art. 2(3)(b)(i)**
- F79** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), **art. 2(3)(b)(i)**
- F80** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), **art. 2(3)(b)(i)**
- F81** Word in Sch. 2 Pt. 3 para. 1(b) inserted (1.7.2003) by The Misuse of Drugs Act 1971 (Modification) Order 2003 (S.I. 2003/1243), **arts. 1, 2(4)(a)**
- F82** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), **art. 2(3)(b)(ii)**
- F83** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), **art. 2(3)(b)(iii)**

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

- F84** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(b\)\(iv\)](#)
- F85** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(b\)\(v\)](#)
- F86** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(b\)\(v\)](#)
- F87** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(b\)\(vi\)](#)
- F88** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(b\)\(vi\)](#)
- F89** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(b\)\(vii\)](#)
- F90** Word in Sch. 2 Pt. 3 para. 1(b) inserted (1.7.2003) by [The Misuse of Drugs Act 1971 \(Modification\) Order 2003 \(S.I. 2003/1243\)](#), [arts. 1, 2\(4\)\(b\)](#)
- F91** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(b\)\(viii\)](#)
- F92** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(b\)\(ix\)](#)
- F93** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(b\)\(ix\)](#)
- F94** Word in Sch. 2 Pt. 3 para. 1(b) inserted (13.6.2012) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2012 \(S.I.2012/1390\)](#), [art. 3\(b\)](#)
- F95** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(b\)\(x\)](#)
- F96** Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(b\)\(xi\)](#)
- F97** Sch. 2 Pt. 3 para. 1(ca) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(c\)](#)
- F98** Words in Sch. 2 Pt. 3 para. 1(d) repealed (26.1.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2008 \(S.I. 2008/3130\)](#), [art. 2\(3\)\(b\)](#)
- F99** Word in Sch. 2 Pt. 3 para. 1(e) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(d\)](#)
- F100** Word in Sch. 2 Pt. 3 para. 1(e) inserted (23.12.2009) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2009 \(S.I. 2009/3209\)](#), [art. 2\(3\)\(d\)](#)

- 2 Any stereoisomeric form of a substance for the time being specified in paragraph 1 of this Part of this Schedule [^{F101}not being phenylpropanolamine.]

Textual Amendments

- F101** Words added by [S.I. 1986/2230](#), [art. 2\(4\)](#)

- 3 Any salt of a substance for the time being specified in paragraph 1 or 2 of this Part of this Schedule.
- 4 Any preparation or other product containing a substance for the time being specified in any of paragraphs 1 to 3 of this Part of this Schedule.

Status: Point in time view as at 24/06/2014.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

PART IV U.K.

MEANING OF CERTAIN EXPRESSIONS USED IN THIS SCHEDULE

For the purposes of this Schedule the following expressions (which are not among those defined in section 37(1) of this Act) have the meanings hereby assigned to them respectively, that is to say—

“cannabinol derivatives” means the following substances, except where contained in cannabis or cannabis resin, namely tetrahydro derivatives of cannabinol and 3-alkyl homologues of cannabinol or of its tetrahydro derivatives;

“coca leaf” means the leaf of any plant of the genus *Erythroxylon* from whose leaves cocaine can be extracted either directly or by chemical transformation;

“concentrate of poppy-straw” means the material produced when poppy-straw has entered into a process for the concentration of its alkaloids;

[^{F102}“khat” means the leaves, stems or shoots of the plant of the species *Catha edulis*;

“medicinal opium” means raw opium which has undergone the process necessary to adapt it for medicinal use in accordance with the requirements of the British Pharmacopoeia, whether it is in the form of powder or is granulated or is in any other form, and whether it is or is not mixed with neutral substances;

“opium poppy” means the plant of the species *Papaver somniferum* L;

“poppy straw” means all parts, except the seeds, of the opium poppy, after mowing;

“raw opium” includes powdered or granulated opium but does not include medicinal opium.

Textual Amendments

F102 Words in Sch. 2 Pt. 4 inserted (24.6.2014) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2014 \(S.I. 2014/1352\)](#), arts. 1, 4

Textual Amendments

F102 Words in Sch. 2 Pt. 4 inserted (24.6.2014) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2014 \(S.I. 2014/1352\)](#), arts. 1, 4

Status:

Point in time view as at 24/06/2014.

Changes to legislation:

There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2.